Stay updated with breaking news from Inhibrx inc . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) shares traded down 4.6% during mid-day trading on Friday . The company traded as low as $21.71 and last traded at $21.87. 6,001 shares changed hands during trading, a decline of 98% from the average session volume of 262,587 shares. The stock had previously closed at $22.93. Several equities […]
Sumitomo Mitsui Financial Group started coverage on shares of Inhibrx (NASDAQ:INBX – Get Rating) in a research note issued to investors on Wednesday morning, Marketbeat reports. The brokerage issued an outperform rating and a $40.00 target price on the stock. A number of other research analysts have also recently issued reports on INBX. JMP Securities […]
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) – Research analysts at Jefferies Financial Group lowered their FY2022 EPS estimates for shares of Inhibrx in a research report issued to clients and investors on Tuesday, March 1st. Jefferies Financial Group analyst M. Yee now expects that the company will earn ($2.69) per share for the year, down […]
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
Inhibrx (NASDAQ:INBX – Get Rating) announced its quarterly earnings data on Sunday. The company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.04, MarketWatch Earnings reports. Inhibrx had a negative return on equity of 150.02% and a negative net margin of 1,093.94%. Shares of INBX stock […]
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today...
/PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic...
Share this article Share this article SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105. Mark Lappe, Inhibrx's CEO commented, "2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering." Phase 1 Dose Escalation Results for INBRX-105 INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody (sdAb) platform that is designed to agonize 4-1BB selectively in the presence of programmed death ligand 1 (PD-L1), a protein that is typically found in the tumor microenvironment and lymphoid tissues.